SPREDs are also implicated in tumorigenesis.79,80) Mutations in SPRED1 have been shown to be a tumor suppressor as they are found at a high frequency of >30% in KIT-driven mucosal melanoma.81) Furthermore, homozygous deletions of SPRED1 contribute to resistance to MAPK-targeted therapy in melanoma patients.82). The gene discussed is SPRED1; the disease is mucosal melanoma.